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OBJECTIVE— Increases in blood pressure and visit-to-visit variability have both been found
to independently increase the likelihood of cardiovascular events in nondiabetic individuals.
This study has investigated whether each may also influence the development of microvascular
complications in type 1 diabetes by examining data from the Diabetes Control and Complica-
tions Trial (DCCT).
RESEARCH DESIGN AND METHODS— Using binary longitudinal multiple logistic
regression, mean systolic (SBP) and diastolic (DBP) blood pressure as well as annual visit-to-visit
variability (SD.SBP and SD.DBP, respectively) was related to the risk of the development/
progression of nephropathy and retinopathy in initially normotensive subjects who did not
become pregnant during the DCCT.
RESULTS— Mean SBP and SD.SBP were independently predictive of albuminuria (odds ratio
1.005 [95% CI 1.002–1.008], P 0.001 and 1.093 [1.069–1.117], P 0.001, respectively, for
1 mmHg change), although SBP variability did not add to mean SBP in predicting retinopathy
(0.999 [0.985–1.013], P 0.93). DBP variability was also independently predictive of nephrop-
athy (1.102 [1.068–1.137], P 0.001) and not of retinopathy (0.991 [0.971–1.010], P 0.37).
Mean SBP was poorly related to SD.SBP (r2 0.01) as was mean DBP with SD. DBP (r2 0.01).
CONCLUSIONS— Visit-to-visit variability in blood pressure consistently independently
added to mean blood pressure in predicting the risk of nephropathy, but not retinopathy, in the
DCCT. This observation could have implications for the management and treatment of blood
pressure in patients with type 1 diabetes.
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H yperglycemia, and the duration of ex-posure to hyperglycemia, explainsonly11% of the risk of developing
microvascular complications in type 1 dia-
betes (1). The remaining 89% of risk must
be explained by other factors, one of which
is the presence of hypertension, which is
known to be especially related to develop-
ment and progression of nephropathy (2–
5). Blood pressure lowering using
antihypertensive agents has been shown to
be successful in slowing the deterioration in
renal function of type 1 diabetic patients
with established renal impairment or pro-
teinuria (6) but to only have an influence on
retinopathy, not nephropathy, at much ear-
lier stages in normotensive patients with
normoalbuminuria (7).
The role of hypertension in the de-
velopment of small-vessel disease there-
fore remains unclear . Certa in ly ,
hypertension is related to the presence
of microalbuminuria in type 1 diabetes,
but it is not known whether it is the
hypertension that gives rise to nephrop-
athy or vice versa (8). Hypertension also
predicts retinopathy and this frequently
coexists with nephropathy, but again it
is uncertain whether high blood pres-
sure gives rise to eye disease directly or
is more a marker that renal disease is
also present.
Recently, in two large study meta-
analyses (9,10), visit-to-visit variability in
systolic blood pressure (SBP) has been
found to be a strong predictor of subse-
quent stroke independent of the mean
SBP. We speculated that blood pressure
variability may also have an influence on
the development of microvascular com-
plications in diabetes. To this end, we
have reranalyzed data from the Diabetes
Control and Complications Trial (DCCT)
to see if blood pressure and its variability
influenced the development of nephrop-
athy and retinopathy in its large group of
type 1 diabetic patients.
RESEARCH DESIGN AND
METHODS
The datasets
We used the publicly accessible datasets
collected by the DCCT. The DCCT was a
9-year follow-up study of 1,441 partici-
pants with type 1 diabetes comparing the
effect of intensive versus conventional
blood glucose management on the devel-
opment of the microvascular complica-
tions of diabetes. At randomization,
patients were stratified into one of two
cohorts. The primary prevention cohort
(n 726) had no evidence of retinopathy
by fundus photography and a urinary al-
bumin excretion rate (AER)40 mg/24 h
(28 g/min). The secondary prevention
cohort (n  715) had only minimal reti-
nopathy and an AER200 mg/24 h (140
g/min). The study participants were
randomized into intensive (n 711) and
conventional (n 730) treatment groups.
Individuals were excluded from the
DCCT study if their SBP was 140
mmHg and/or their diastolic blood pres-
sure (DBP) was90 mmHg or they were
treated with antihypertensive medication
(11). The following DCCT SAS files were
used in our analyses (retinopathy:
ms2exprt .sas7bdat; nephropathy:
ms3exprt.sas7bdat).
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Blood pressure and definition of
events
The effect of SBP and DBP on microvas-
cular complications was assessed by ex-
amining annual measurements during
the DCCT in all subjects who were not
pregnant at any stage during the study
(n  1,261: 761 male and 500 female,
median age 28 years [interquartile
range {IQR} 22–33]). Blood pressure
was measured with a random-zero
sphygmomanometer twice in a sitting
posi t ion. Var iabi l i ty of SBP/DBP
(mmHg) was calculated as the SD of the
between-visit measurements. Because
the SD is influenced by the number of
observations, the generalized estimat-
ing equation regression models were
weighted by the number of SBP/DBP
measurements. This ranged from 1 to
10 (median 6), being the same for SBP
and DBP. The blood pressure value re-
corded was used irrespective of whether
the patient was started on antihyperten-
sive treatment during the course of the
DCCT.
Severity of retinopathy was deter-
mined by the 25-point Early Diabetic
Retinopathy Treatment Study (EDRTS)
interim score (12). The development
and progression of sustained retinopa-
thy was defined as a change from base-
line of three or more units on the
EDRTS score on any two successive
evaluations as predefined by the DCCT
investigators. During the 9 years of fol-
low-up, 334 people developed sus-
tained retinopathy, 114 of whom were
in the intensive treatment group. Ne-
phropathy was defined as the develop-
ment of an AER 40 mg/24 h (28 g/
min) on any annual eva luat ion,
providing that the baseline AER was
40 mg/24 h (28 g/min). The mean
age was 27 years (range 13–39). Just
over half (n  761, 52.8%) were men.
Seventy-three secondary-prevention
patients had an AER 40 mg/24 h at
baseline but 200 mg/24 h, so a sepa-
rate analysis was performed excluding
these individuals. Primary- or second-
ary-intervention grouping was based
solely on retinopathy, which did not al-
low a similar analysis based on ne-
phropathy development.
Average BMI was 23.4 kg/m2; 2%
had a BMI 30 kg/m2. Nearly all partici-
pants were Caucasian. The median dis-
ease duration was 4 years. Approximately
one-fifth declared themselves as current
smokers.
Statistical methods
We used the generalized estimating equa-
tion (GEE) with a logit link to assess the
effect of covariates on the odds of the de-
velopment and progression of both reti-
nopathy and nephropathy over repeated
time points (13,14). The GEE logistic re-
gression method, which is implemented
in the Stata statistical computer package
(15), allows for the correlation between
successive repeated measurements on the
same subject. Covariates to blood pres-
sure indexes in the models included age
(years) at entry into the DCCT, duration
of diabetes (months) prior to DCCT, sex,
randomization treatment (intensive ver-
sus conventional), A1C (%) at baseline,
and A1C (averaged across the study). The
size, direction, and statistical significance
of relationships were estimated by the
odds ratio (OR) with 95% CIs. The OR is
an approximation to the relative risk (16).
The 95% CIs were estimated from Wald
robust SEs (i.e., using the empirical [in-
formation sandwich] variance estimates).
An arbitrary level of 5% statistical signifi-
cance (two tailed) was assumed. Un-
weighted linear regression was used to
relate blood pressure variability (SD) to
mean blood pressure averaged over all
study visits. The Stata statistical computer
package was used to analyze the data
(StataCorp), and the Analyze-It add-in for
Microsoft Excel was used for linear
correlation.
RESULTS— The average of each pa-
tients’ mean SBP during the DCCT was
(means  SD) 114.8  8.5 mmHg and
DBP was 73.7  5.8 mmHg. Intraindi-
vidual variability (SD) of SBP (SD.SBP)
and DBP ranged from 0 to 24 mmHg
(median 8.0 mmHg) and 1 to 14 mmHg
(median 6.5 mmHg), respectively, being
s imi l a r fo r bo th randomiza t ion
treatments.
Table 1 shows the relationship be-
tween both mean SBP and SBP variability
and the development or progression in
retinopathy and nephropathy. Table 2
gives the equivalent data for DBP. While a
relationship between retinopathy and
mean SBP approached statistical signifi-
cance, there was none with SD.SBP, either
overall or by randomization treatment
(Table 1). In contrast, there was a signifi-
cant independent relationship between
both mean SBP and SD.SBP and nephrop-
athy in each randomization group and
when the groups were combined (Table
1). Table 2 shows an association between
mean DBP and retinopathy risk, with DBP
variability contributing no further,
whereas, overall, the opposite was true for
Table 1—SBP longitudinal multiple logistic regression models for nephropathy and retinop-
athy excluding pregnant patients
Nephropathy Retinopathy
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
All Patients
Model 1
SBP (mmHg) 1.006 (1.003–1.010) 0.001 1.002 (1.000–1.005) 0.014
Model 2
SBP (mmHg) 1.005 (1.002–1.008) 0.001 1.002 (1.000–1.005) 0.014
SD.SBP (mmHg) 1.093 (1.069–1.117) 0.001 0.999 (0.985–1.013) 0.93
Intensive
Model 1
SBP (mmHg) 1.007 (1.001–1.014) 0.015 1.008 (1.004)–1.012) 0.001
Model 2
SBP (mmHg) 1.006 (1.000–1.012) 0.023 1.008 (1.004–1.012) 0.001
SD.SBP (mmHg) 1.065 (1.022–1.109) 0.002 1.015 (0.989–1.042) 0.24
Conventional
Model 1
SBP (mmHg) 1.004 (1.000–1.008) 0.018 0.999 (0.996–1.002) 0.70
Model 2
SBP (mmHg) 1.003 (0.999–1.007) 0.056 0.999 (0.996–1.002) 0.76
SD.SBP (mmHg) 1.111 (1.083–1.139) 0.001 0.99 (0.974–1.006) 0.23
Model 1 relates to mean SBP alone, model 2 incorporates visit-to-visit SD.SBP. Models were adjusted for age,
sex, disease duration, A1C (baseline), and A1C (mean). Model for all patients further adjusted for random-
ization treatment. Models weighted for number of SBP measurements. Odds ratio for SBP per 1-mmHg
increase.
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nephropathy with DBP variability. Figure
1A shows the risk of nephropathy accord-
ing to tertiles of both mean SBP and
SD.SBP relative to subjects in the lowest
tertile for each, with Fig. 1B showing the
same data for DBP. Restricting analysis to
only those individuals with a baseline
AER40 mg/24 h made no difference to
the findings.
Looking at primary- and secondary-
intervention groups separately, the only
signal for blood pressure variability (SBP
or DBP) influencing retinopathy among
the eight groups examined (primary/
secondary, intensive/conventional,
SD.SBP/SD.DBP) was in the SD.SBP of the
intensively treated primary prevention
patients (hazard ratio 1.144[95% CI
1.089 –1.203]), P  0.001), although
this, understandably, was in the group
with the least number of subjects showing
a consistent three-step change (n  23).
The linear relationship between mean
SBP and SBP variability was poor, al-
though statistically significant, due to the
large number of subjects involved (r 
0.09, P 0.0013) (Fig. 2A), with SD.SBP
rising by 0.3 mmHg for every 10-mmHg
rise in mean SBP. Likewise, changes in
mean DBP explained little of any change
in DBP variability (r  0.06, P  0.026)
(Fig. 2B), with SD.DBP falling by 0.2
mmHg for every 10-mmHg rise in mean
DBP. There was more of an association
between variability in SBP and variability
in DBP (r  0.29, P  0.0001).
CONCLUSIONS— This study has
shown that annual visit-to-visit variability
in both SBP and DBP are associated with
the development of nephropathy in type 1
diabetes, independently of their mean
values. While mean DBP was related to
the appearance of retinopathy, blood
pressure variability was less of a feature of
this microvascular complication.
Looked at from the basis of patients
participating in the DCCT, the magnitude
of the contribution of SBP variability to
nephropathy is at least as much as that
which can be attributed to changes in
mean SBP (Fig. 1). Indeed, using the
models in Table 1, it means that a DCCT
patient on the 97.5th centile of SBP vari-
ability (SD 13.3 mmHg) has 2.34 times
the nephropathy risk of a patient on the
2.5th centile (SD 3.7 mmHg) for a given
mean SBP. By comparison, a patient on
the 97.5th centile of mean SBP (129
mmHg) has 1.15 times the nephrop-
Figure 1—Risk of nephropathy according to rising tertiles of mean SBP and visit-to-visit SBP
variability (SD.SBP) (A) andmean DBP and DBP variability (SD.DBP) (B). The lowest tertile for
mean blood pressure and SD blood pressure is the reference. Data adjusted as in Table 1.
Table 2—DBP longitudinal multiple logistic regression models for nephropathy and retinop-
athy excluding pregnant patients
Nephropathy Retinopathy
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
All patients
Model 1
DBP (mmHg) 0.998 (0.995–1.004) 0.95 1.009 (1.006–1.013) 0.001
Model 2
DBP (mmHg) 1.000 (0.995–1.004) 0.89 1.009 (1.006–1.013) 0.001
SD.DBP (mmHg) 1.102 (1.068–1.137) 0.001 0.991 (0.971–1.010) 0.37
Intensive
Model 1
DBP (mmHg) 1.015 (1.007–1.023) 0.001 1.006 (1.001–1.012) 0.01
Model 2
DBP (mmHg) 1.016 (1.007–1.024) 0.001 1.006 (1.001–1.012) 0.01
SD.DBP (mmHg) 0.954 (0.901–1.009) 0.1 0.994 (0.962–1.028) 0.76
Conventional
Model 1
DBP (mmHg) 0.991 (0.986–0.997) 0.005 1.011 (1.007–1.015) 0.001
Model 2
DBP (mmHg) 0.993 (0.987–0.998) 0.01 1.011 (1.007–1.015) 0.001
SD.DBP (mmHg) 1.16 (1.118–1.204) 0.001 0.986 (0.962–1.011) 0.29
Model 1 relates to mean DBP alone. Model 2 incorporates visit-to-visit SD.DBP. Models adjusted for as for
SBP.
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athy risk of a patient on the 2.5th centile
(101.1 mmHg) for a given SBP variability.
These findings are in keeping with re-
cent studies that have shown that in var-
ious population studies not particularly
targeting patients with diabetes that visit-
to-visit variability in SBP is a powerful
predictor of stroke and coronary events,
independent of mean SBP (9,10). As type
1 diabetic patients with diabetic nephrop-
athy are at an especial risk of these mac-
rovascular complications (17), it may
point to SBP variability being a common
risk factor for both.
It is perhaps surprising that visit-to-
visit blood pressure variability itself (both
SBP and DBP) was not more closely re-
lated to the respective mean blood pres-
sure values. Mean SBP and mean DBP
explained 1% of the variance (r2) in
SD.SBP and SD.DBP. Indeed, linear re-
gression suggested that the magnitude of
any change in variability associated with
changes in mean BP and variability was
modest and for DBP even suggested a fall
in variability as mean DBP rose. This lack
of concordance makes the association be-
tween blood pressure variability and ne-
phropathy all the more likely to be due to
an independent effect, as it has been
found without attempting to statistically
tease out the relative contribution of two
closely related blood pressure factors.
Mention must be made of the fact that
SBP variability did have a statistically sig-
nificant effect on retinopathy develop-
ment in the intensively treated primary-
prevention cohort. However, this was the
sole retinopathy signal in all the analyses
performed and was found in the group
with the fewest of patients having events.
By comparison, there was over six times
the number of patients experiencing reti-
nopathy worsening in the conventionally
treated secondary-prevention group.
Therefore, although this is perhaps one of
the clinically most important groups, the
possibility of this finding being a type 1
error cannot be excluded.
The more consistent influence of
blood pressure and its variability predict-
ing nephropathy rather than retinopathy
is in contrast to that of glycemia. In an-
other analysis of DCCT data, both mean
A1C and A1C variability have been found
to be considerably more predictive of ret-
inopathy changes than in nephropathy
(18).
There remains the question of
whether blood pressure is having an in-
fluence on albuminuria or nephropathy is
having an influence on blood pressure. A
previous examination of DCCT data were
unable to provide a definitive answer,
since although 90% of subjects who de-
veloped nephropathy did so before the
diagnosis of hypertension, a rise in DBP
preceded the rise in albuminuria among
intensively treated patients (19). If ne-
phropathy does lead to hypertension,
then this current analysis of the same
dataset suggests that nephropathy would
Figure 2—Relationship between SBP variability (SD.SBP) and mean SBP (A) and between DBP
variability (SD.DBP) and mean DBP (B).
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need influence both mean blood pressure
and its visit-to-visit variability. Since av-
erage blood pressure and blood pressure
variability are not closely related, it means
nephropathy would probably need to af-
fect both by two different mechanisms.
Rather, it seems more plausible that there
be an independent effect of raised blood
pressure and of episodic hypertension on
the development of albuminuria.
Should increasing blood pressure
variability prove to have an influence on
the development of diabetic nephropa-
thy, then the effect of different antihyper-
tensive drug classes on this instability
may be of relevance. For some time, ACE
inhibitors and angiotensin 2 receptor an-
tagonists (A2As) have been the first-line
antihypertensive drug of choice due to
their beneficial effect on blood pressure
and an especial effect on albuminuria.
However, ACE inhibitors and A2As lead
to relatively increased SBP variability
compared with other drug classes, such as
calcium channel blockers and nonloop
diuretics, and only calcium channel
blockers reduce visit-to-visit SBP variabil-
ity compared with placebo (20). There-
fore, although drugs affecting the renin-
angoiotensin system have theoretical
advantages over other antihypertensive
classes in preventing nephropathy, their
effect on blood pressure variability may
not be one of them.
This observation on the effect of anti-
hypertensive classes on blood pressure
variability, together with our current find-
ings, may help explain the results from
the recent Renin-Angiotensin System
Study (RASS), which investigated the ef-
fect of enalapril and losartan compared
with placebo on the progression of renal
disease in a group of 285 normotensive
normoalbuminuric type 1 diabetic pa-
tients (7). Despite a significant reduction
in SBP and DBP with the two antihyper-
tensive drugs, there were no beneficial re-
nal histological changes compared with
placebo, nor were there any reductions
the development of microalbuminuria
(actually being higher among patients
taking the A2A) or in the decline in glo-
merular filtration rate. As most patients in
the DCCT were at a similar primary-
prevention stage in their type 1 diabetes
to those in the RASS trial and were also
initially normotensive, it is possible that
any benefits related to reduction in mean
blood pressure by the ACE inhibitor and
A2A were being mitigated by a lack of
effect on blood pressure variability. This
is in marked contrast to eye disease in the
RASS, where both enalapril and losartan
led to marked reduction in the develop-
ment of retinopathy, a complication that
was found to be less related to blood pres-
sure variability in this current study.
Finally, the data presented here also
have implications for the interpretation of
blood pressure measurements in patients
with type 1 diabetes. Received wisdom is
that antihypertensive treatment should
only be instituted if hypertension can be
confirmed on the basis of several raised
blood pressure measurements on separate
days (21). As for both coronary heart dis-
ease and stroke risk (22), the assumption
that blood pressure need not require
treatment when it is not consistently
raised may now need to be reconsidered
for preventing the development of dia-
betic nephropathy.
In conclusion, in contrast to retinop-
athy, visit-to-visit variability in blood
pressure consistently added to mean
blood pressure in predicting the risk of
developing albuminuria among the pa-
tients participating in the DCCT. This ob-
servation could have implications for the
management and treatment of blood
pressure in patients with type 1 diabetes.
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